SCHEMBL6799166

SCHEMBL6799166

O=C(Nc1ccc(NC(=O)c2ccccc2-c2ccc(C(F)(F)F)cc2)cc1)Nc1ccccn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.59
CHRNB4 P30926 1/20 0.59
CHRNA3 P32297 1/20 0.59
CHRNA4 P43681 1/20 0.59
TRPV1 Q8NER1 4/20 0.58
SMO Q99835 1/20 0.54
LMNA P02545 1/20 0.53
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
ADORA3 P0DMS8 1/20 0.52
PIM1 P11309 1/20 0.52
ADORA2A P29274 1/20 0.52
ADORA2B P29275 1/20 0.52
ADORA1 P30542 1/20 0.52
FLT3 P36888 1/20 0.52
PIM3 Q86V86 1/20 0.52
AURKB Q96GD4 1/20 0.52
ALDH1A1 P00352 1/20 0.51
APOB P04114 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6801569 0.91 TRPV1 (0.68) CHRNB2CHRNB4CHRNA3CHRNA4TRPV1
SCHEMBL6794545 0.90 TRPV1 (0.60) CHRNB2CHRNB4CHRNA3CHRNA4TRPV1
SCHEMBL6793626 0.89 NAMPT (0.56) CHRNB2CHRNB4CHRNA3CHRNA4TRPV1
SCHEMBL6799294 0.87 KMT2A (0.56) CHRNB2CHRNB4CHRNA3CHRNA4TRPV1
SCHEMBL6792071 0.86 TRPV1 (0.78) CHRNB2CHRNB4CHRNA3CHRNA4TRPV1
SCHEMBL6792600 0.85 KDR (0.59) CHRNB2CHRNB4CHRNA3CHRNA4TRPV1
SCHEMBL6794893 0.85 POLB (0.53) CHRNB2CHRNB4CHRNA3CHRNA4TRPV1
SCHEMBL6795020 0.85 CHRNB2 (0.52) CHRNB2CHRNB4CHRNA3CHRNA4TRPV1
SCHEMBL6789824 0.85 DHODH (0.54) CHRNB2CHRNB4CHRNA3CHRNA4TRPV1
SCHEMBL6789833 0.85 DHODH (0.54) CHRNB2CHRNB4CHRNA3CHRNA4TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 CHRNB2 1763/4885CHRNB4 2366/4885CHRNA3 3192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.